Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: Patients With Drug-resistant Focal Epilepsy, SEEG as Part of Presurgical Evaluation
Interventions: Direct Electric Stimulation (DES); Other
Lead sponsor: Hospices Civils de Lyon; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions: VTS-K; Drug
Lead sponsor: Theresa Jacob, PhD, MPH; Other
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Metastatic Breast Cancer
Interventions: Lapatinib; Drug
Lead sponsor: Gary Schwartz; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Aurora, Colorado • Lebanon, New Hampshire • Lake Success, New York

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: INR731, Enzalutamide, Abiraterone, Androgen deprivation therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Prostate Cancer Metastatic
Interventions: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 48
States / cities: Orange, California • Palo Alto, California • Riverside, California + 41 more

Conditions: Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions: Delamanid, Optimized Background Regimen (OBR), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Adults
Interventions: Adagrasib, Eltrombopag + adagrasib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Focal Segmental Glomerulosclerosis
Interventions: LIPOSORBER® LA-15; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Up to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 10
States / cities: Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more

Conditions: Stigma, Social, Substance Use
Interventions: RESTART; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Portsmouth, Ohio

Conditions: Hyperlipidemia, Diabetes, Hypertension
Interventions: Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management; Device · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 142
States / cities: Anchorage, Alaska • Bakersfield, California • Irvine, California + 117 more

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: HIV-1-infection
Interventions: Biktarvy Tab; Drug
Lead sponsor: Southampton Healthcare, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy
Interventions: ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI); Drug · Biological · Procedure
Lead sponsor: Robert Flavell, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Epilepsy, Temporal Lobe
Interventions: NRTX-1001; Biological
Lead sponsor: Neurona Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more

Conditions: TB Multi-drug Resistant
Interventions: SQ109, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Depression, Treatment Resistant Depression
Interventions: clinical assessments; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatitis B, Chronic
Interventions: Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions: Birinapant (TL32711); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Links Between Epileptic Activity, Sleep Disruption and Mental Content During Sleep

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Feasibility and Acceptability of a Stigma Text Message Intervention for People Who Use Drugs

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Antiviral Therapy and HIV in the Female Genital Tract

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

Computational Psychiatric Approach to Depression

Long-Term Lamivudine Therapy for Chronic Hepatitis B

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer